Publications:
Cass AR, Shepherd AJ, Asirot RL, Mahajan M, Nizami MQ. A comparison
of the Male Osteoporosis Risk Estimation Score (MORES) and the FRAX™ in
identifying men at risk for osteoporosis. Annals of Family Medicine. July/August 2016; 14(4): 365-369. doi:10.1370/afm.1947
Shepherd AJ, Howrey BT, Cass AR, Wilkinson GS. Osteoporosis therapy after fracture in elderly men. Journal of Clinical Outcomes Management. 2013; 53(7): 495-499.
Cass AR, Shepherd AJ. Validation of the male osteoporosis risk estimation score (MORES) in a primary care setting. Journal of the American Board of Family Medicine. 2013; 26(4): 436-444.
Shepherd AJ, Cass AR, Ray L, Tan A, Wilkinson GS. Treatment for older men with fractures. Osteoporosis International. 2012. 23(3): 1041-1051.
Baillargeon J, Kuo YF, Lin YL, Wilkinson GS, Goodwin JS.
Osteonecrosis of the jaw in older osteoporosis patients treated with
intravenous bisphosphonates. The Annals of Pharmacotherapy. 2011. 45: 1199-1206.
Shepherd AJ, Cass AR, Ray L, Wilkinson GS. (May 5-8) “Post-Fracture
Treatment for Osteoporosis in Elderly Males.” Paper presented at IOF
World Congress on Osteoporosis. Florence, Italy.
Shepherd AJ, Cass AR, Ray L. Determining risk of vertebral
osteoporosis in men: validation of the male osteoporosis risk estimation
score. J Am Board Fam Med. 2010; 23(2): 186-94.
Berenson AB, Rahman M, Wilkinson G. Racial differences in the
correlates of bone mineral content/density and age at peak among
reproductive-aged women. Osteoporosis Int. 2009; 20:1439-49.
Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Response: Re:
Intravenous bisphosphonate therapy and inflammatory conditions or
surgery of the jaw: a population-based analysis. J Natl Cancer Inst.
2008; 100:155-156.
Shepherd AJ, Cass AR, Carlson CA, Ray L. Development and internal
validation of the male osteoporosis risk estimation score. Ann Fam Med.
2007; 5(6): 540-6.
Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous
bisphosphonate therapy and inflammatory conditions or surgery of the
jaw: a population-based analysis. J Natl Cancer Inst. 2007;99:1016-24.
Cass AR, Shepherd AJ, Carlson CA. Osteoporosis risk assessment and
ethnicity: validation and comparison of two clinical risk stratification
instruments. J Gen Intern Med. 2006; 21(6): 630-5.
McNearney TA, Shepherd AJ, Chhabra A, Goel N. Primary Care House
staff Attitudes Towards Osteoporosis Management. South Med J. 2006;
99(5):461-6.
Shepherd, AJ. An Overview of Osteoporosis. Altern Ther Health Med. 2004, 10(2):26-33.
Funding:
All funding is listed as total costs (direct costs plus indirect costs)
Cass, AR: A comparative analysis of the FRAX® and the male osteoporosis risk estimation score. TAFP. 04/2012-03/2013. $5,000.
Cass, AR (PI), Shepherd, AJ: Clinical Validation of the MORES in a Primary Care Population. AHRQ R03. 9/08-09/11, $99,882.
Shepherd, AJ (PI), Wilkinson, G, Cass, AR: Has the rate of
osteoporosis treatment in older men with fractures improved? The Joint
AAFP/F-AAFP Grant Awards Program. 12/08-11/09, $29,579.
Shepherd, AJ (PI), Cass, AR: Validation of the Male Osteoporosis Risk
Estimation (MORE) Index in the NHANES IV Dataset. The Joint AAFP/F-AAFP
Grant Awards Program. 3/06-2/07, $23,685.
Cass, AR (PI), Shepherd, AJ: Clinical Stratification of Osteoporosis
Risk in Women from an Ethnically Diverse Population. The Joint
AAFP/F-AAFP Grant Awards Program. 9/02-02/04, $20,000.